These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 31685543)

  • 1. Transcriptionally Active Androgen Receptor Splice Variants Promote Hepatocellular Carcinoma Progression.
    Dauki AM; Blachly JS; Kautto EA; Ezzat S; Abdel-Rahman MH; Coss CC
    Cancer Res; 2020 Feb; 80(3):561-575. PubMed ID: 31685543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Splicing factor PRPF6 upregulates oncogenic androgen receptor signaling pathway in hepatocellular carcinoma.
    Song H; Sun N; Lin L; Wei S; Zeng K; Liu W; Wang C; Zhong X; Wang M; Wang S; Zhou B; Lv C; Liu W; Zhao Y
    Cancer Sci; 2020 Oct; 111(10):3665-3678. PubMed ID: 32745318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptor (AR)/miR-520f-3p/SOX9 signaling is involved in altering hepatocellular carcinoma (HCC) cell sensitivity to the Sorafenib therapy under hypoxia via increasing cancer stem cells phenotype.
    Xiao Y; Sun Y; Liu G; Zhao J; Gao Y; Yeh S; Gong L; Chang C
    Cancer Lett; 2019 Mar; 444():175-187. PubMed ID: 30448543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olaparib and enzalutamide synergistically suppress HCC progression via the AR-mediated miR-146a-5p/BRCA1 signaling.
    Zhao J; Sun Y; Lin H; Chou F; Xiao Y; Jin R; Cai X; Chang C
    FASEB J; 2020 Apr; 34(4):5877-5891. PubMed ID: 32134529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acetylcholine acts on androgen receptor to promote the migration and invasion but inhibit the apoptosis of human hepatocarcinoma.
    Nie H; Cao Q; Zhu L; Gong Y; Gu J; He Z
    PLoS One; 2013; 8(4):e61678. PubMed ID: 23620780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance and mechanism of androgen receptor overexpression and androgen receptor/mechanistic target of rapamycin cross-talk in hepatocellular carcinoma.
    Zhang H; Li XX; Yang Y; Zhang Y; Wang HY; Zheng XFS
    Hepatology; 2018 Jun; 67(6):2271-2286. PubMed ID: 29220539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Constitutively Active Androgen Receptor in Hepatocellular Carcinoma.
    Montgomery EJ; Xing E; Campbell MJ; Li PK; Blachly JS; Tsung A; Coss CC
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The miR-367-3p Increases Sorafenib Chemotherapy Efficacy to Suppress Hepatocellular Carcinoma Metastasis through Altering the Androgen Receptor Signals.
    Xu J; Lin H; Li G; Sun Y; Chen J; Shi L; Cai X; Chang C
    EBioMedicine; 2016 Oct; 12():55-67. PubMed ID: 27688096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen activates PEG10 to promote carcinogenesis in hepatic cancer cells.
    Jie X; Lang C; Jian Q; Chaoqun L; Dehua Y; Yi S; Yanping J; Luokun X; Qiuping Z; Hui W; Feili G; Boquan J; Youxin J; Jinquan T
    Oncogene; 2007 Aug; 26(39):5741-51. PubMed ID: 17369855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen/androgen receptor axis maintains and promotes cancer cell stemness through direct activation of Nanog transcription in hepatocellular carcinoma.
    Jiang L; Shan J; Shen J; Wang Y; Yan P; Liu L; Zhao W; Xu Y; Zhu W; Su L; Chen J; Cheng F; Yao H; Xu H; Qian C; Liang Z
    Oncotarget; 2016 Jun; 7(24):36814-36828. PubMed ID: 27167111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma.
    Ma WL; Hsu CL; Wu MH; Wu CT; Wu CC; Lai JJ; Jou YS; Chen CW; Yeh S; Chang C
    Gastroenterology; 2008 Sep; 135(3):947-55, 955.e1-5. PubMed ID: 18639551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma.
    Jiang G; Shi L; Zheng X; Zhang X; Wu K; Liu B; Yan P; Liang X; Yu T; Wang Y; Cai X
    Aging (Albany NY); 2020 Jun; 12(12):11466-11484. PubMed ID: 32579541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emodin succinyl ester inhibits malignant proliferation and migration of hepatocellular carcinoma by suppressing the interaction of AR and EZH2.
    Khan H; Jia W; Yu Z; Zaib T; Feng J; Jiang Y; Song H; Bai Y; Yang B; Feng H
    Biomed Pharmacother; 2020 Aug; 128():110244. PubMed ID: 32464306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of androgen receptor induces ID1 and promotes hepatocellular carcinoma cell migration and invasion.
    Ao J; Meng J; Zhu L; Nie H; Yang C; Li J; Gu J; Lin Q; Long W; Dong X; Li C
    Mol Oncol; 2012 Oct; 6(5):507-15. PubMed ID: 22819717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen receptor signaling in hepatocellular carcinoma and pancreatic cancers.
    Kanda T; Jiang X; Yokosuka O
    World J Gastroenterol; 2014 Jul; 20(28):9229-36. PubMed ID: 25071315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth.
    Mashima T; Okabe S; Seimiya H
    Mol Pharmacol; 2010 Nov; 78(5):846-54. PubMed ID: 20709811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mu-opioid receptor is a molecular marker for poor prognosis in hepatocellular carcinoma and represents a potential therapeutic target.
    Chen DT; Pan JH; Chen YH; Xing W; Yan Y; Yuan YF; Zeng WA
    Br J Anaesth; 2019 Jun; 122(6):e157-e167. PubMed ID: 30915986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
    Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
    Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells.
    Shafi AA; Putluri V; Arnold JM; Tsouko E; Maity S; Roberts JM; Coarfa C; Frigo DE; Putluri N; Sreekumar A; Weigel NL
    Oncotarget; 2015 Oct; 6(31):31997-2012. PubMed ID: 26378018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.